• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血浆置换疗法治疗静脉注射丙种球蛋白难治性川崎病的疗效。

Efficacy of plasma exchange therapy for Kawasaki disease intractable to intravenous gamma-globulin.

机构信息

Department of Pediatrics, Yokohama City University School of Medicine, 3-9 Fuku-ura, Kanazawa-ku, Yokohama, 236-0004, Japan,

出版信息

Mod Rheumatol. 2004;14(1):43-7. doi: 10.1007/s10165-003-0264-3.

DOI:10.1007/s10165-003-0264-3
PMID:17028804
Abstract

Kawasaki disease (KD) causes coronary artery lesions (CALs) in 500 Japanese children each year. Intravenous gamma-globulin (IVGG) decreases the incidence of these lesions from 25% to 8% of the total KD cases. We examined whether plasma exchange is a safe and effective prophylaxis against CALs in children with KD intractable to IVGG therapy. Eighty-nine children with KD at high risk of CALs were selected on the basis of increases in fractional changes in inflammatory markers such as white blood cell count, neutrophil count, and C-reactive protein between the baseline and 1-2 days after IVGG treatment. Of 105 children who received a second course of IVGG therapy because the initial course was ineffective, plasma exchange (PE) was performed in 46 children who had not responded to the second IVGG treatment. The outcome was compared with the results when a third course of IVGG therapy was given to the other 59 children. No complications occurred with the plasma exchange therapy. CALs developed in only 8 of the 46 children (17.3%) who underwent plasma exchange, but they occurred in 24 of the 59 (40.7%) who had received a third course of IVGG therapy (P << 0.0012). We concluded that PE was a safe, effective prophylactic measure against CALs in children with KD intractable to IVGG therapy. PE should be performed at an early stage, as soon as fractional increases in inflammatory markers are found after IVGG therapy.

摘要

川崎病(KD)每年导致 500 名日本儿童发生冠状动脉病变(CALs)。静脉注射丙种球蛋白(IVGG)可将这些病变的发生率从总 KD 病例的 25%降低到 8%。我们研究了在对 IVGG 治疗有反应的 KD 患儿中,血浆置换是否是预防 CALs 的安全有效方法。根据 IVGG 治疗后 1-2 天炎症标志物(如白细胞计数、中性粒细胞计数和 C 反应蛋白)的分数变化,选择了 89 名有 CALs 高危风险的 KD 患儿。在 105 名因初始 IVGG 治疗无效而接受第二次 IVGG 治疗的患儿中,有 46 名对第二次 IVGG 治疗无反应的患儿接受了血浆置换(PE)。将结果与另外 59 名接受第三次 IVGG 治疗的患儿的结果进行比较。血浆置换治疗无并发症。在接受血浆置换的 46 名患儿中,只有 8 名(17.3%)发生 CALs,但在接受第三次 IVGG 治疗的 59 名患儿中,有 24 名(40.7%)发生 CALs(P << 0.0012)。我们得出结论,PE 是治疗对 IVGG 治疗有反应的 KD 患儿 CALs 的安全有效预防措施。PE 应在 IVGG 治疗后发现炎症标志物分数增加时尽早进行。

相似文献

1
Efficacy of plasma exchange therapy for Kawasaki disease intractable to intravenous gamma-globulin.血浆置换疗法治疗静脉注射丙种球蛋白难治性川崎病的疗效。
Mod Rheumatol. 2004;14(1):43-7. doi: 10.1007/s10165-003-0264-3.
2
Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease.川崎病静脉注射丙种球蛋白治疗后冠状动脉病变的预测因素
J Pediatr. 2000 Aug;137(2):177-80. doi: 10.1067/mpd.2000.107890.
3
Meta-analysis of the results of intravenous gamma globulin treatment of coronary artery lesions in Kawasaki disease.川崎病冠状动脉病变静脉注射丙种球蛋白治疗结果的Meta分析
Mod Rheumatol. 2004;14(5):361-6. doi: 10.1007/s10165-004-0324-3.
4
[Plasma exchange therapy for Kawasaki disease refractory to intravenous immunoglobulin].[静脉注射免疫球蛋白难治性川崎病的血浆置换疗法]
Nihon Rinsho. 2008 Feb;66(2):349-54.
5
Plasminogen activator inhibitor-1 in patients with Kawasaki disease: diagnostic value for the prediction of coronary artery lesion and implication for a new mode of therapy.川崎病患者中的纤溶酶原激活物抑制剂-1:对冠状动脉病变预测的诊断价值及对新治疗模式的启示
Pediatr Res. 2003 Jun;53(6):983-8. doi: 10.1203/01.PDR.0000061566.63383.F4. Epub 2003 Mar 5.
6
Intravenous gamma-globulin therapy improves hypercytokinemia in the acute phase of Kawasaki disease.静脉注射丙种球蛋白治疗可改善川崎病急性期的细胞因子血症。
Mod Rheumatol. 2004 Dec;14(6):447-52. doi: 10.3109/s10165-004-0341-2.
7
Coronary risk factors in Kawasaki disease treated with additional gammaglobulin.接受额外丙种球蛋白治疗的川崎病患者的冠状动脉危险因素。
Arch Dis Child. 2004 Aug;89(8):776-80. doi: 10.1136/adc.2003.032748.
8
Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose.川崎病中冠状动脉异常的患病率高度依赖于γ球蛋白剂量,但与水杨酸盐剂量无关。
J Pediatr. 1997 Dec;131(6):888-93. doi: 10.1016/s0022-3476(97)70038-6.
9
Prognostic impact of vascular leakage in acute Kawasaki disease.急性川崎病中血管渗漏的预后影响
Circulation. 2003 Jul 22;108(3):325-30. doi: 10.1161/01.CIR.0000079166.93475.5F. Epub 2003 Jun 30.
10
The Benefits and Respective Side-Effects of PE Therapy for Intractable Kawasaki Disease.PE疗法治疗难治性川崎病的益处及相应副作用
J Clin Med. 2021 Mar 4;10(5):1062. doi: 10.3390/jcm10051062.

引用本文的文献

1
Diagnosis, Progress, and Treatment Update of Kawasaki Disease.川崎病的诊断、进展和治疗更新。
Int J Mol Sci. 2023 Sep 11;24(18):13948. doi: 10.3390/ijms241813948.
2
Kawasaki Disease: Pathology, Risks, and Management.川崎病:病理学、风险和管理。
Vasc Health Risk Manag. 2022 Jun 10;18:407-416. doi: 10.2147/VHRM.S291762. eCollection 2022.
3
Anti-inflammatory Treatment of Kawasaki Disease: Comparison of Current Guidelines and Perspectives.川崎病的抗炎治疗:现行指南与观点比较
Front Med (Lausanne). 2021 Nov 30;8:738850. doi: 10.3389/fmed.2021.738850. eCollection 2021.
4
The Benefits and Respective Side-Effects of PE Therapy for Intractable Kawasaki Disease.PE疗法治疗难治性川崎病的益处及相应副作用
J Clin Med. 2021 Mar 4;10(5):1062. doi: 10.3390/jcm10051062.
5
Structure equation model and neural network analyses to predict coronary artery lesions in Kawasaki disease: a single-centre retrospective study.结构方程模型和神经网络分析预测川崎病冠状动脉病变:单中心回顾性研究。
Sci Rep. 2020 Jul 17;10(1):11868. doi: 10.1038/s41598-020-68657-0.
6
Kawasaki Disease Complicated with Cerebral Vasculitis and Severe Encephalitis.川崎病合并脑血管炎和重症脑炎
Ann Indian Acad Neurol. 2020 Mar-Apr;23(2):228-232. doi: 10.4103/aian.AIAN_271_18. Epub 2020 Feb 25.
7
History and Future of Treatment for Acute Stage Kawasaki Disease.川崎病急性期治疗的历史与未来
Korean Circ J. 2020 Feb;50(2):112-119. doi: 10.4070/kcj.2019.0290. Epub 2019 Dec 3.
8
Refractory Kawasaki disease: diagnostic and management challenges.难治性川崎病:诊断与管理挑战
Pediatric Health Med Ther. 2019 Oct 30;10:131-139. doi: 10.2147/PHMT.S165935. eCollection 2019.
9
White Blood Cell and Neutrophil Counts and Response to Intravenous Immunoglobulin in Kawasaki Disease.川崎病中白细胞和中性粒细胞计数及对静脉注射免疫球蛋白的反应
Glob Pediatr Health. 2019 Oct 25;6:2333794X19884826. doi: 10.1177/2333794X19884826. eCollection 2019.
10
Safety and efficacy of plasma exchange therapy for Kawasaki disease in children in intensive care unit: case series.重症监护病房中儿童川崎病血浆置换治疗的安全性和有效性:病例系列
JA Clin Rep. 2018;4(1):25. doi: 10.1186/s40981-018-0156-3. Epub 2018 Mar 6.